Literatura académica sobre el tema "Heparin"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Heparin".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Heparin"
Zvibel, I., E. Halay y L. M. Reid. "Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors". Molecular and Cellular Biology 11, n.º 1 (enero de 1991): 108–16. http://dx.doi.org/10.1128/mcb.11.1.108-116.1991.
Texto completoZvibel, I., E. Halay y L. M. Reid. "Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors." Molecular and Cellular Biology 11, n.º 1 (enero de 1991): 108–16. http://dx.doi.org/10.1128/mcb.11.1.108.
Texto completoBar-Ner, M., A. Eldor, L. Wasserman, Y. Matzner, IR Cohen, Z. Fuks y I. Vlodavsky. "Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species". Blood 70, n.º 2 (1 de agosto de 1987): 551–57. http://dx.doi.org/10.1182/blood.v70.2.551.551.
Texto completoBar-Ner, M., A. Eldor, L. Wasserman, Y. Matzner, IR Cohen, Z. Fuks y I. Vlodavsky. "Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species". Blood 70, n.º 2 (1 de agosto de 1987): 551–57. http://dx.doi.org/10.1182/blood.v70.2.551.bloodjournal702551.
Texto completoFareed, Jawed, Adrian Sonevytsky, Omer Iqbal, Walter P. Jeske, Massimo Iacobelli y Debra Hoppensteadt. "Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications." Blood 108, n.º 11 (16 de noviembre de 2006): 1626. http://dx.doi.org/10.1182/blood.v108.11.1626.1626.
Texto completoPinhal, Maria A. S., Isabel A. N. Santos, Irani F. Silva, Carl P. Dietrich y Helena B. Nader. "Minimum Fragments of the Heparin Molecule Able to Produce the Accumulation and Change of the Sulfation Pattern of an Antithrombotic Heparan Sulfate from Endothelial Cells". Thrombosis and Haemostasis 74, n.º 04 (1995): 1169–74. http://dx.doi.org/10.1055/s-0038-1649898.
Texto completoHovingh, P., M. Piepkorn y A. Linker. "Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates". Biochemical Journal 237, n.º 2 (15 de julio de 1986): 573–81. http://dx.doi.org/10.1042/bj2370573.
Texto completoSieme, Daniel, Christian Griesinger y Nasrollah Rezaei-Ghaleh. "Metal Binding to Sodium Heparin Monitored by Quadrupolar NMR". International Journal of Molecular Sciences 23, n.º 21 (29 de octubre de 2022): 13185. http://dx.doi.org/10.3390/ijms232113185.
Texto completoDiamond, M. S., R. Alon, C. A. Parkos, M. T. Quinn y T. A. Springer. "Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1)." Journal of Cell Biology 130, n.º 6 (15 de septiembre de 1995): 1473–82. http://dx.doi.org/10.1083/jcb.130.6.1473.
Texto completoBasic-Micic, M., K. Krupinski, A. Thalhammer, C. Dechent, Ch Rauschenbach y H. K. Breddin. "Beeinflußt niedermolekulares Heparin die Thrombozytenfunktion?" Hämostaseologie 09, n.º 05 (septiembre de 1989): 248–57. http://dx.doi.org/10.1055/s-0038-1655278.
Texto completoTesis sobre el tema "Heparin"
Raghuraman, Arjun. "Designing Non-saccharide Heparin/Heparan Sulfate Mimics". Online version available 8/19/2013, 2008. http://hdl.handle.net/10156/2269.
Texto completoCarelli, Guareide [UNESP]. "Associação de doses baixas de heparina não fracionada e de heparina de baixo peso molecular na prevenção de trombose venosa experimental". Universidade Estadual Paulista (UNESP), 2003. http://hdl.handle.net/11449/88962.
Texto completoA heparina é um glicosaminoglicano sulfatado, de cadeia longa, que vem sendo largamente utilizada, desde meados do século passado, no tratamento e profilaxia das tromboses arteriais e venosas e cuja utilização permitiu o desenvolvimento das cirurgias cardíaca e vascular. As heparinas de baixo peso molecular (HBPM) são frações ou fragmentos da heparina separados do complexo polissacarídico por extração com solvente ou por gel filtração, ou por clivagem química ou enzimática aplicada antes dessa separação física. No presente artigo são revistos os diversos aspectos da estrutura, mecanismo de ação, farmacocinética, monitorização laboratorial e aplicações clínicas de ambos os tipos de substâncias, sendo chamada a atenção para as diferenças entre elas. As HBPM tendem a substituir a heparina não fracionada, na maior parte de suas indicações, por serem de mais simples utilização e apresentarem maior eficácia e segurança em algumas indicações, embora sejam de custo mais alto.
Heparin is a long sulfated glucosaminoglicane chain has been used in the treatment and prophylaxis of arterial and venous thombosis since the 50’s of last century. Its use also aided the development of cardiac and vascular surgery. Low molecular weight heparins (LMWH) are fractions or fragments of heparin separated from the polysaccharide complex by solvent extraction or gel filtration, or by chemical or enzymatic cleavage, before the extraction. In this article the main aspects of structure, mechanism of action, pharmacokinetics, laboratorial control, and clinical indications of both kinds of substances are reviewed and their main differences emphasized. Despite their high cost, LMWH presently tend to substitute unfractionated heparin in the majority of indications because of its simpler use, high efficacy and security in some cases.
Noti, Christian. "Synthesis of heparin oligosaccharides and the creation of heparin microarrays /". Zürich : ETH, 2007. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=17150.
Texto completoAlbig, Thomas. "Synthese und Untersuchung von Heparin-Prodrugs auf Glyceridbasis /". [S.l.] : [s.n.], 1986. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=7990.
Texto completoJaime, Rodríguez Juan Carlos. "Unveiling Heparin and Heparan Sulfate Conformations : a Journey into Paramagnetic NMR Analysis". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASF016.
Texto completoHeparin (HP) and heparan sulfates (HS) are linear and sulfated polysaccharides that play various biological roles, including cell growth, adhesion, viral recognition, and cancer metastasis. Their molecular diversity and sulfation pattern contribute to their biological versatility. Furthermore, their conformational flexibility has been studied through methods such as X-ray crystallography and NMR. Despite advancements, interpreting these features remains challenging, especially for long saccharides. This thesis proposes the use of paramagnetic NMR, particularly pseudo-contact shifts (PCS) measurements, in studying the conformation of HS molecules. Results obtained on an HS octasaccharide show a correlation between experimental PCS and molecular dynamics simulations, suggesting specific conformations of IdoA motifs. These findings expand the applications of paramagnetic NMR, paving the way for a thorough analysis of protein-polysaccharide interactions
Nazir, Ahmad Mohamad Farha. "The role of heparin and heparin-binding growth factors in pre-eclampsia". Thesis, Middlesex University, 2016. http://eprints.mdx.ac.uk/21321/.
Texto completoKRISHNASAMY, CHANDRAVEL. "MOLECULAR MODELING STUDIES OF HEPARIN AND HEPARIN MIMETICS BINDING TO COAGULATION PROTEINS". VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/18.
Texto completoSachchidanand. "Heparin binding to fibronectin". Thesis, University of Oxford, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.393457.
Texto completoEvans, Dyfed Ll. "The heparin activateable serpins". Thesis, University of Cambridge, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.385390.
Texto completoFreitas, Cristiane Fonseca. "Efeitos do Bay 41-2272 na hipertensão pulmonar experimental em cães anestesiados". [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/308951.
Texto completoTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-09T08:05:23Z (GMT). No. of bitstreams: 1 Freitas_CristianeFonseca_D.pdf: 2119434 bytes, checksum: 58a318beb1d3946d852e010325a6187c (MD5) Previous issue date: 2007
Resumo: Neste estudo, investigamos os efeitos protetores do BAY 41-2272 sobre a hipertensao pulmonar induzida pelo complexo heparina-protamina e hipoxia em cães anestesiados. Os animais foram anestesiados com pentobarbital sodico (Hypnol, 30mg/kg, iv) combinado com citrato de fentanila (0,01 mg/kg/h, i.v.) e diazepam (0,25mg/kg/h, iv). A hipertensao pulmonar pelo complexo heparina-protamina foi induzida com a administracao de 500 UI/kg de heparina, seguida da administracao de protamina (10 mg/kg). A interacao heparina-protamina causou aumento de aproximadamente 350% da pressao media da arteria pulmonar (PMAP), acompanhado de aumento significativo do indice de resistencia vascular pulmonar (IRVP) e da pressao capilar pulmonar (PcP). Este aumento foi significativo 2 min apos a injecao de protamina, mantendo-se significativamente elevado ate aproximadamente 5 minutos apos administracao da mesma. Ao mesmo tempo em que se detectou a hipertensao pulmonar, observamos reducao significativa da pressao arterial media (PAM). Observamos ainda um aumento significativo da frequencia cardiaca (FC) aos 2 minutos apos administracao da protamina com discreta diminuicao do indice cardiaco (IC). O indice de resistencia vascular sistemica (IRVS) nao sofreu alteracoes significativas. A saturacao do oxigenio (SpO2) foi significativamente diminuida apos a formacao do complexo heparina-protamina. Nos animais tratados com BAY 41-2272 (10 /kg/min, i.v.), observamos reducao marcante do aumento da PMAP, do IRVP e da PcP. Por outro lado, este tratamento potencializou a reducao da PAM. Alem disso, o BAY 41-2272 reduziu significantemente o IRVS e aumentou a FC. A diminuicao da SpO2 foi atenuada significativamente pelo BAY 41- 2272. Os niveis plasmaticos de GMPc foram dosados aos 2 min apos a formacao do complexo heparina-protamina, tendo-se mostrado elevados no grupo tratado com o BAY41-2272. O tempo de tromboplastina parcial ativado (TTPA) nao apresentou alteração significativa no tratamento com o BAY 41-2272. O veiculo do BAY 41-2272 (DMSO 30%) nao alterou significativamente os parametros estudados. A hipertensao pulmonar por hipoxia foi induzida com a instalacao de uma baixa tensao de oxigenio (FiO2=12%). Nesta circunstancia, a PMAP elevou-se em aproximadamente 280% aos 5 minutos, mantendo-se significativamente elevada ate 15 minutos apos instalacao da hipoxia. A elevacao da PMAP foi acompanhada de aumentos significativos no IRVP e PcP. A PAM, IRVS, FC e IC nao apresentaram alterações significativas. A SpO2 diminuiu na presenca da hipoxia. O tratamento com BAY 41-2272 (10 /kg/min, i.v.), reduziu significativamente a PMAP, PcP e IRVP. O IRVS foi significativamente potencializado pelo BAY 41-2272. A PAM, FC e IC nao alteraram significativamente. A diminuicao da SpO2 foi atenuada significativamente pelo BAY 41- 2272. Os niveis plasmaticos de GMPc elevaram-se significativamente no grupo tratado com o BAY 41-2272. Em conclusao, o BAY 41-2272 atenuou a acao vasoconstritora pulmonar induzida pelo complexo heparina-protamina e hipoxia levando a uma prevencao da hipertensao pulmonar.
Doutorado
Farmacologia
Doutor em Farmacologia
Libros sobre el tema "Heparin"
1960-, Warkentin Theodore E. y Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 4a ed. New York: Informa Healthcare USA, 2007.
Buscar texto completo1960-, Warkentin Theodore E. y Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 3a ed. New York: Marcel Dekker, 2004.
Buscar texto completoWarkentin, Theodore E. y Andreas Greinacher. Heparin-induced thrombocytopenia. 4a ed. New York: Informa Healthcare, 2007.
Buscar texto completo1960-, Warkentin Theodore E. y Greinacher Andreas, eds. Heparin-induced thrombocytopenia. New York: Dekker, 2000.
Buscar texto completo1960-, Warkentin Theodore E. y Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 2a ed. New York: Dekker, 2001.
Buscar texto completoLane, David A., Ingemar Björk y Ulf Lindahl, eds. Heparin and Related Polysaccharides. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4899-2444-5.
Texto completo1949-, Lane D. A., Björk Ingemar y Lindahl Ulf 1939-, eds. Heparin and related polysaccharides. New York: Plenum Press, 1992.
Buscar texto completoBarrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.
Buscar texto completoChang, Shau-Feng. Studies on structure, heparin-binding, and gene expression of hepatic lipase. München: Dissertationsverlag NG Kopierladen, 1993.
Buscar texto completoinstitutet, Karolinska, ed. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity: Effects of heparin and a low molecular weight heparin fragment (Fragmin®). Stockholm: Acta medica Scandinavica, 1988.
Buscar texto completoCapítulos de libros sobre el tema "Heparin"
Harr, Jeffrey N., Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan et al. "Heparin". En Encyclopedia of Intensive Care Medicine, 1071–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_715.
Texto completoRoth, Elliot J. "Heparin". En Encyclopedia of Clinical Neuropsychology, 1686–87. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_2219.
Texto completoPetroianu, Georg y Peter Michael Osswald. "Heparin". En Anästhesie in Frage und Antwort, 79–81. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-05715-5_28.
Texto completoPetroianu, Georg y Peter Michael Osswald. "Heparin". En Anästhesie in Frage und Antwort, 99–101. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-662-05717-9_43.
Texto completoRoth, Elliot J. "Heparin". En Encyclopedia of Clinical Neuropsychology, 1–2. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-56782-2_2219-2.
Texto completoWilson, John Fawcett. "Heparin". En The Immunoassay Kit Directory, 1555. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0679-5_26.
Texto completoWatkins, Evan y Daniel Thomas Ginat. "Heparin". En Neuroimaging Pharmacopoeia, 257–60. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12715-6_33.
Texto completoWatkins, Evan, Daniel Thomas Ginat y Juan E. Small. "Heparin". En Neuroimaging Pharmacopoeia, 313–16. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08774-5_44.
Texto completoBährle-Rapp, Marina. "Heparin". En Springer Lexikon Kosmetik und Körperpflege, 254. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-71095-0_4679.
Texto completoRoth, Elliot J. "Heparin". En Encyclopedia of Clinical Neuropsychology, 1236–37. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_2219.
Texto completoActas de conferencias sobre el tema "Heparin"
Eldor, A., M. Bar-Ner, L. Wasserman, Y. matzner, Z. Fuks y I. Viodavsky. "HEPARIN AND NON-ANTICOAGULANT HEPARINS INHIBIT HEPARANASE ACTIVITY IN NORMAL AND MALIGNANT CELLS:POSSIBLE THERAPEUTIC USE IN PREVENTION OF EXTRAVASATION AND DISSEMINATION OF BLOOD BORNE CELLS". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643664.
Texto completoBorowska, A., D. Lauri, A. Maggi, E. Dejana, G. de Gaetano y J. Pangrazzi. "IMPAIREMENT OF PRIMARY HAEMOSTASIS BY LMW-HEPARINS". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643172.
Texto completoMaggi, A., T. W. Barrowcliffe, E. Gray, M. B. Donati, R. E. Merton y I. Pangrazzi. "RELATIONSHIP BETWEEN HAEMORRHAGIC AND LIPASE-RET EASING PROPERTIES OF HEPARIN AND LMV HEPARIN". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642929.
Texto completoDawes, J. y D. S. Pepper. "A COMPARISON OF THE BINDING OF ANTITHROMBIN III AND HEPARIN COFACTOR II TO HEPARINS, NATURALLY OCCURRING GLYCOSAMINOGLYCANS AND OTHER SULPHATED POLYMERS". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642827.
Texto completoMessmore, H., B. Griffin, J. Seghatchian y E. Coyne. "HIGH CONCENTRATIONS OF HEPARIN ARE MORE INHIBITORY TO PLATE- AGGREGATION IN-VITRO THAN ARE LOW MOLECULAR WEIGHT HEPARINS AND HEPARINOIDS AT THE SAME CONCENTRATION". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644186.
Texto completoOrdu, Y., J. Augustin, E. V. Hodenberg, V. Bode y J. Harenberg. "COMPARATIVE CLINICAL PHARMACOLOGY OF LOW MOLECULAR WEIGHT HEPARINS IN MAN". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643228.
Texto completoJackson, Craig M. "A DEFINITION OF HEPARIN ANTICOAGULANT POTENCY APPLICABLE TO ALL HEPARINS AND HEPARIN-LIKE SUBSTANCES AND ITS PRACTICAL APPLICATION IN ASSAYING HEPARIN". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642928.
Texto completoZimmerman, R. A., C. T. Rieger, K. Hübner, C. W. Harenber y W. Kübler. "EXPERIMENTAL THROMBUS FORMATION AND HAEMOSTASIS OF DIFFERENT LOW MOLECULAR WEIGHT HEPARINS AND DOSAGES". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644162.
Texto completoRathjen, A. y Carolyn L. Geczy. "PRODUCTION AND CHARACTERISATION OF MONOCLONAL ANTIBODIES AGAINST HEPARIN Deborah". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644188.
Texto completoFenichel, R. L., W. Carmint, B. Small y J. Willis. "COMPARISON OF THE ANTITHROMBOTIC, ANTICLOTTING AND ANTIPLATELET AGGREGATORY ACTIVITIES OFLOW MOLECULAR WEIGHT RD HEPARIN WITH HEPARIN". En XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644854.
Texto completoInformes sobre el tema "Heparin"
Carlin, Stephanie, Andrew M. Morris, Zainab B. Abdurrahman, Jacob J. Bailey, Martin E. Betts, William Ciccotelli, Bradley J. Langford et al. Heparin Anticoagulation for Hospitalized Patients with COVID-19. Ontario COVID-19 Science Advisory Table, septiembre de 2021. http://dx.doi.org/10.47326/ocsat.2021.02.41.1.0.
Texto completoUpchurch, G. R., Valeri Jr., Khuri C. R., Rohrer S. F., Welch M. J. y G. N. The Effect of Heparin on Fibrinolytic Activity and Platelet Function. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 1995. http://dx.doi.org/10.21236/ada360274.
Texto completoSalomon, David. The Role of Heparin-Binding EGF-Like Growth Factor in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, octubre de 1995. http://dx.doi.org/10.21236/ada300394.
Texto completoKhuri, S. F., C. R. Valeri, J. Loscalzo, M. Weinstein y V. Birjiniuk. Heparin Causes Platelet Dysfunction and Induces Fibrinolysis Before the Institution of Cardiopulmonary Bypass. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 1995. http://dx.doi.org/10.21236/ada360259.
Texto completoChen, Chen, Peng Chen, Xia Liu y Hua Li. Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients with Retinal Detachment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, agosto de 2021. http://dx.doi.org/10.37766/inplasy2021.8.0117.
Texto completoLi, Rui, Xiang Gao, Tao Zhou, Yunjie Li, Jianhui Wang y Peirong Zhang. Regional citrate versus heparin anticoagulation for CRRT in critically ill patients: a meta-analysis of RCTS. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, diciembre de 2021. http://dx.doi.org/10.37766/inplasy2021.12.0093.
Texto completoChan, Shan-Ho, Cheng-Kai Huang, Po-Nien Hou y Jay Wu. Meta-Analysis of the Effectiveness of Heparin in Suppressing Physiological Myocardial FDG Uptake in PET/CT. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, marzo de 2023. http://dx.doi.org/10.37766/inplasy2023.3.0015.
Texto completoWei, Qingqing, Weiying Wang, Guobin Miao, Li Li, Ge Wang, Chang Meng y Peng Liu. Aspirin Versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis in Patients after Postoperative Joint Surgery: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, febrero de 2023. http://dx.doi.org/10.37766/inplasy2023.2.0117.
Texto completoLin, Yun-Kuan, Yu-Ning Huang y Jen-Hung Wang. Effects of heparin on venom-induced consumption coagulopathy: protocol for a systematic review, meta-analysis, and trial sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, febrero de 2024. http://dx.doi.org/10.37766/inplasy2024.2.0070.
Texto completohuang, kun, yan sun y hai jiang. Effect of low molecular weight heparin combined with aspirin on pregnancy outcomes of unexplained recurrent abortion: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, octubre de 2023. http://dx.doi.org/10.37766/inplasy2023.10.0005.
Texto completo